Concepedia

Jose R. Pereira

JR

Statistics

Publications

8

Citations

5.6K

H-Index

8

Active since

2003

Affiliations

Asklepios Fachkliniken München-Gauting(Current)

Medical University of Vienna

Merck KGaA, Darmstadt (Germany)

St. James's Hospital

The Maria Sklodowska-Curie National Research Institute of Oncology

Jose R. Pereira is an author at Asklepios Fachkliniken München-Gauting specializing in non-small cell lung cancer treatment, lung cancer, and non-small cell lung cancer therapy.

Publications per year

2003–2023

8

Publications

8

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

Nasser H. Hanna, Frances A. Shepherd, Frank V. Fossella et al. · Journal of Clinical Oncology · 2004 · 2.4K citations · Full text

, , +15

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

Robert Pirker, Jose R. Pereira, Aleksandra Szczęsna et al. · The Lancet · 2009 · 1.4K citations · Full text

, , +13

Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group

Frank V. Fossella, Jose R. Pereira, Joachim von Pawel et al. · Journal of Clinical Oncology · 2003 · 943 citations

, , +15

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

Robert Pirker, Jose R. Pereira, Joachim von Pawel et al. · The Lancet Oncology · 2011 · 574 citations

, , +17

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy

Nasser H. Hanna, Frances A. Shepherd, Frank V. Fossella et al. · Journal of Clinical Oncology · 2023 · 167 citations

, , +15

1–5 of 8